Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

INTRODUCTION: Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) demonstrated clinical and neuroradiologic efficacy and safety in the Phase 3 DEFINE and CONFIRM trials, and in the extension study (ENDORSE), in patients with relapsing–remitting multiple sclerosis (RRMS). This...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Ralf, Giovannoni, Gavin, Phillips, J. Theodore, Fox, Robert J., Zhang, Annie, Marantz, Jing L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919132/
https://www.ncbi.nlm.nih.gov/pubmed/26932146
http://dx.doi.org/10.1007/s40120-016-0042-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919132/
https://www.ncbi.nlm.nih.gov/pubmed/26932146
http://dx.doi.org/10.1007/s40120-016-0042-8

Ejemplares similares